UY30921A1 - Tetrahidro-pirazolo-piridinas ligados a carbono como moduladores de catepsina s - Google Patents

Tetrahidro-pirazolo-piridinas ligados a carbono como moduladores de catepsina s

Info

Publication number
UY30921A1
UY30921A1 UY30921A UY30921A UY30921A1 UY 30921 A1 UY30921 A1 UY 30921A1 UY 30921 A UY30921 A UY 30921A UY 30921 A UY30921 A UY 30921A UY 30921 A1 UY30921 A1 UY 30921A1
Authority
UY
Uruguay
Prior art keywords
modulators
piridinas
catepsina
tetrahidro
pirazolo
Prior art date
Application number
UY30921A
Other languages
English (en)
Inventor
John J M Wiener
Alvah T Wickboldt
Kevin L Tays
Steven P Meduna
Cheryl A Grice
Elizabeth Ann Gleason
James P Edwards
Hui Cai
Frank U Axe
Michael K Ameriks
Original Assignee
Sunesis Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals filed Critical Sunesis Pharmaceuticals
Publication of UY30921A1 publication Critical patent/UY30921A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Se describen compuestos de tetrahidro-pirazolo-piridina ligados a carbono, que son utiles como moduladores de la catepsina S. Dichos compuestos pueden utilizarse en composiciones farmacéuticas y métodos para el tratamiento de enfermedades, trastornos, y afecciones intermediadas por la actividad de la catepsina S, tales como psoriasis, dolor, escleorosis multiple, ateroescleorosis, y artritis reumatoidea.
UY30921A 2007-02-15 2008-02-15 Tetrahidro-pirazolo-piridinas ligados a carbono como moduladores de catepsina s UY30921A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88997707P 2007-02-15 2007-02-15
US12/031,010 US20080200454A1 (en) 2007-02-15 2008-02-14 Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s

Publications (1)

Publication Number Publication Date
UY30921A1 true UY30921A1 (es) 2008-09-02

Family

ID=39512608

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30921A UY30921A1 (es) 2007-02-15 2008-02-15 Tetrahidro-pirazolo-piridinas ligados a carbono como moduladores de catepsina s

Country Status (8)

Country Link
US (1) US20080200454A1 (es)
AR (1) AR065377A1 (es)
CL (1) CL2008000495A1 (es)
PA (1) PA8769601A1 (es)
PE (1) PE20090162A1 (es)
TW (1) TW200843743A (es)
UY (1) UY30921A1 (es)
WO (1) WO2008100618A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009102937A1 (en) * 2008-02-14 2009-08-20 Sunesis Pharmaceuticals, Inc. Processes for the preparation of carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
WO2011069149A2 (en) * 2009-12-04 2011-06-09 Dcb-Usa Llc Cathepsin s inhibitors
WO2011094890A1 (en) * 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
AU2011270701B2 (en) * 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
KR20130115311A (ko) * 2010-11-24 2013-10-21 알러간, 인코포레이티드 S1p 수용체의 조절제
US10464896B2 (en) 2015-06-11 2019-11-05 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
CN106916094B (zh) * 2017-01-11 2019-06-04 青岛昌泰和生物科技有限公司 一种吲哚二酮化合物的制备方法
WO2019074241A1 (ko) * 2017-10-11 2019-04-18 정원혁 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제
EP3946332A1 (en) 2019-04-05 2022-02-09 Université de Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2262674T3 (es) * 2000-08-14 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
US20070117785A1 (en) * 2000-08-14 2007-05-24 Butler Christopher R Substituted pyrazoles and methods of treatment with substituted pyrazoles
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
DK1309591T3 (da) * 2000-08-14 2007-03-26 Ortho Mcneil Pharm Inc Substituerede pyrazoler
US7332494B2 (en) * 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
US20050101587A9 (en) * 2000-08-14 2005-05-12 Butler Christopher R. Method for treating allergies using substituted pyrazoles
BRPI0113286B8 (pt) * 2000-08-14 2021-05-25 Johnson & Johnson pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
MXPA03001963A (es) * 2000-09-06 2004-03-18 Johnson & Johnson Un metodo para tratar alergias usando pirazoles sustituidos.
EP1315741A2 (en) * 2000-09-06 2003-06-04 Ortho-McNeil Pharmaceutical, Inc. A method for treating allergies
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
US20030073672A1 (en) * 2001-09-05 2003-04-17 Breitenbucher J. Guy Method for treating allergies using substituted pyrazoles
SE0201977D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201976D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0304640D0 (en) * 2003-02-28 2003-04-02 Novartis Ag Organic compounds
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7326715B2 (en) * 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7687515B2 (en) * 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives

Also Published As

Publication number Publication date
PA8769601A1 (es) 2009-03-31
PE20090162A1 (es) 2009-03-12
AR065377A1 (es) 2009-06-03
WO2008100618A3 (en) 2008-10-02
US20080200454A1 (en) 2008-08-21
TW200843743A (en) 2008-11-16
CL2008000495A1 (es) 2008-11-03
WO2008100618A2 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
UY30921A1 (es) Tetrahidro-pirazolo-piridinas ligados a carbono como moduladores de catepsina s
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
ECSP12011908A (es) OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO
CL2008000790A1 (es) Compuestos derivados de purina sustituida; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como aterosclerosis, artritis, psoriasis y cancer.
CR11027A (es) Modulares 2-aminopirimidina del receptor de histamina h4
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
UY32629A (es) Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c.
CR8718A (es) Compuesto de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
GT201000015A (es) Sulfonamidas como moduladores de trpms
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
UY30454A1 (es) Moduladores tiazolopirimidina de trpv1
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
ECSP099581A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso
BR112014014809A2 (pt) composições farmacêuticas compreendendo glitazonas e ativadores de nrf2
UY30479A1 (es) Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4
CL2012001673A1 (es) Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras.
CY1112725T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
UY31540A1 (es) Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
CL2011001428A1 (es) Compuestos derivados de amidas del acido tetrahidroisoquinolil-4-oxobutirico; composicion farmaceutica; y uso en el tratamiento de desordenes o enfermedades mediadas por canales de potasio kcnq2/3, tales como dolor, epilepsia. incontinencia urinaria, ansiedad, entre otras.
UY30229A1 (es) Tetrahidro-pirimidoazepinas como moduladores de trpv1
UY30330A1 (es) Nuevas formas polimorfas de (2s)-(4e)-n-metil-5-(3-(5-isopropoxipiridin)il)-4-penten-2-amina
UY31243A1 (es) Compuestos de 2-aza-biciclo[2.2.2]octano y usos para los mismos